cysteine has been researched along with lapatinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hardy, KD; Nelson, SD; Papageorgiou, I; Rettie, AE; Unadkat, JD; Wahlin, MD | 1 |
| Dai, C; He, S; Hu, H; Lou, Q; Wang, L; Wu, J; You, X; Zhang, J; Zhao, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cysteine and lapatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for cysteine and lapatinib
| Article | Year |
|---|---|
Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
Topics: Biotransformation; Cell Line, Tumor; Cell Survival; Cysteine; Cytochrome P-450 CYP3A; Dexamethasone; Glutathione; Hepatocytes; Humans; Lapatinib; Liver; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rifampin | 2014 |
Cysteine-based redox-responsive nanoparticles for small-molecule agent delivery.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Cysteine; Drug Delivery Systems; Drug Liberation; Erythrocytes; Female; Hydrogen-Ion Concentration; Lapatinib; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Nanoparticles; Oxidation-Reduction; Rats, Sprague-Dawley; Tissue Distribution | 2019 |